Cara Therapeutic Ownership
| CARA Stock | USD 5.12 0.08 1.59% |
Shares in Circulation | First Issued 2012-12-31 | Previous Quarter 54.7 M | Current Value 54.8 M | Avarage Shares Outstanding 36.7 M | Quarterly Volatility 15.2 M |
Cara |
Cara Stock Ownership Analysis
About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 21.0. Cara Therapeutic had not issued any dividends in recent years. The entity had 1:12 split on the 31st of December 2024. Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people. For more info on Cara Therapeutic please contact Christopher Posner at 203 406 3700 or go to https://www.caratherapeutics.com.Besides selling stocks to institutional investors, Cara Therapeutic also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cara Therapeutic's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cara Therapeutic's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cara Therapeutic Quarterly Liabilities And Stockholders Equity |
|
Cara Therapeutic Insider Trades History
About 16.0% of Cara Therapeutic are currently held by insiders. Unlike Cara Therapeutic's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cara Therapeutic's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cara Therapeutic's insider trades
Cara Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cara Therapeutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cara Therapeutic backward and forwards among themselves. Cara Therapeutic's institutional investor refers to the entity that pools money to purchase Cara Therapeutic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-09-30 | 327.2 K | Two Sigma Investments Llc | 2024-09-30 | 240.9 K | Fmr Inc | 2024-09-30 | 210.3 K | State Street Corp | 2024-09-30 | 180.4 K | Adar1 Capital Management Llc | 2024-09-30 | 159.5 K | Lpl Financial Corp | 2024-09-30 | 149 K | Susquehanna International Group, Llp | 2024-09-30 | 127.6 K | Xtx Topco Ltd | 2024-09-30 | 94.7 K | Tudor Investment Corp Et Al | 2024-09-30 | 93.1 K | Vanguard Group Inc | 2024-09-30 | 2.2 M | Chescapmanager Llc | 2024-09-30 | 1.7 M |
Cara Therapeutic Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cara Therapeutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cara Therapeutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cara Therapeutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cara Therapeutic Outstanding Bonds
Cara Therapeutic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cara Therapeutic uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cara bonds can be classified according to their maturity, which is the date when Cara Therapeutic has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Cara Therapeutic Corporate Filings
F4 | 6th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 27th of January 2025 Other Reports | ViewVerify | |
8K | 21st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 20th of December 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.00) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.